[S-01-1] A genetic approach to uncover a novel target molecule for human demyelinating diseases
Molecular targeted therapy has rapidly been developing in human intractable demyelinating diseases. However, it is still extremely difficult to cure demyelinating diseases and repair damaged tissues, especially progressive form of multiple sclerosis. To develop a novel therapy for intractable demyelinating diseases, it is critical to uncover novel target molecules involved in disease cascades. Large scale genetic studies and bioinformatics as well as genetically engineered animals are powerful tools for discovering novel risk molecules and examining functions of these molecules. Combined neuropathological and neuroimaging approaches are also useful to clarify disease cascades. In this symposium, four distinguished speakers give lectures on genetic, immunopathological, molecular imaging, and genetically engineered mouse approaches to identify novel molecules involved in pathomechanisms of human demyelinating diseases.
Jan. 2009 - Sep. 2009 Assistant Professor, Graduate School of Medical Sciences, Department of Neurology, Kyushu University
Oct. 2009 - Sep. 2012 Associate Professor, Graduate School of Medical Sciences, Department of Clinical Neuroimmunology, Kyushu University
Oct. 2012 - Jun.2014 Research Associate Professor, Graduate School of Medical Sciences, Department of Neurology, Kyushu University
Jul. 2014 - Jun. 2015 Associate Professor, Graduate School of Medical Sciences, Department of Neurological Therapeutics, Kyushu University
Jul. 2015 - Jun. 2016 Lecturer, Graduate School of Medical Sciences, Department of Neurology, Kyushu University
Jul. 2016 - Present Clinical Associate Professor, Department of Neurology, Kyushu University Hospital
From 2012 to 2014, he joined the Multiple Sclerosis Laboratory at the Department of Neurology in the UCSF School of Medicine
Abstract password authentication.
Password is written on a pocket program and name badge.